Introduction
An increase in the incidence of HF has been reported in patients with RA. The risk of HF was previously shown to be approximately 2-fold higher in patients with RA than in the general population, and is known to markedly contribute to mortality in these patients 1−2) . The increased incidence of cardiovascular (CV) events 3) and higher prevalence of diastolic dysfunction 4) may account for the development of HF in patients with RA. A disease duration of more than 10 years, rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibody positivity, the presence of severe extra-articular manifestations, and higher levels of C-reactive protein (CRP) have been associated with an increase in the risk of CV events 3) , all of which are listed as poor prognostic factors and are among the main considerations for biologics.
Nevertheless, TNF-α inhibitor therapy is contraindicated in patients with New York Heart Association (NYHA)
class III/IV HF 5−6)
. We herein described a 46-year-old male patient with active RA and severe congestive HF, who has been administered TCZ for 5 years without adverse events.
Case report
A 41-year old male was transferred to our hospital in (Fig. 1a) . Thalium-201 myocardial scintigraphy at rest showed markedly decreased perfusion over the posterior and lateral walls of the left ventricle (Fig. 1b) . The patient underwent coronary arterial stenting to the stenotic left anterior descending artery, which was followed by the administration of angiotensin II blockers, anti-platelet therapy, and β-adrenergic receptor antagonists. He moved to our area thereafter and discontinued taking medication based on his own judgment.
On admission, his height and body weight were 165 We herein described the long-term administration of tocilizumab (TCZ) to a patient with rheumatoid arthritis (RA) complicated by three vessel coronary artery disease and severe heart failure (HF). A 41-year-old male was admitted to our hospital with exacerbated RA and congestive HF. Cardiac ultrasonography revealed diffuse hypokinesis with a left ventricular ejection fraction (LVEF) of 16.8% and New York Heart Association (NYHA) class III/IV HF. Swelling and tenderness were noted in most of his joints. Methotrexate (MTX) was initiated during his hospitalization and TCZ was introduced 6 months later. Our patient has been treated with MTX and TCZ for five years without any adverse events, and RA and HF have remained stable. Although it may be anecdotal, we suggest that TCZ may be used as a treatment option in patients with RA complicated by severe HF.
Key words rheumatoid arthritis; heart failure; NYHA III/IV; treatment; tocilizumab cm and 80 kg, respectively, and his body mass index was 29.4 cm/m 2 . His body temperature was 38.4°C, blood pressure was 106/-mmHg, and heart rate was 117 beats per minutes. His oxygen saturation while breathing ambient air was 98%. A third heart sound was audible, while neither cardiac murmur nor pulmonary wheezing was detected. Leg edema was absent. Swelling and tenderness were found in almost all joints examined and swan neck deformities and ulnar deviations were noted in the bilateral hands. Biochemical tests showed a C-reactive protein (CRP) level of 24.4 mg/d and His RF and anti-CCP antibody levels were 161.8 IU/ml (normal < 10 IU/ml) and 69.8 U/ml (normal < 4.4 U/ml), respectively. His serum IgG, C3, C4, and matrix metaroproteinase-3 levels were 1310 mg/dl (normal 907−1950 mg/dl), 177 mg/dl (normal 65−135 mg/dl), 22.5 mg/dl (normal 10.9−39.7 mg/dl), and 258.7 ng/ml (normal 36.9−121.0 ng/ml), respectively, and his brain natriuretic peptide (BNP) concentration was 232.4 pg/ml (normal < 18.4 pg/ml). An X-P examination of the chest revealed cardiomegaly without pleural effusion ( Fig. 2a) and cardiac ultrasonography showed severe diffuse hypokinesis (EF of 16.8%) and marked dilatation of the left ventricle (left ventricular diastolic diameter (7) of 77.9 mm) (Fig. 3) . A granular 'sparkling' appearance with increased echogenicity characteristic to cardiac amyloidosis was not detected. An X-P of the bilateral hands and feet revealed the prominent erosion of bone, ankylosis, and joint space narrowing. The diagnosis of administer TCZ intravenously, the patient has not been rehospitalized because an exacerbation in HF, and DAS 28-ESR remains within moderate disease activity (Fig. 4 ).
An X-P of the chest had shown no further deterioration of heart failure (Fig. 2b) . He is currently receiving 6 mg of MTX weekly and no PSL, and is using a mobility scooter.
Discussion
We herein described a RA patient with high disease .
Our patient first presented to a different hospital in 2007
and was diagnosed with 3-vessel coronary artery disease and severe HF with diffuse hypokinesis in the left ventricle at the age of 41. Although our patient appeared to be younger than the peak age of onset, his anti-CCP antibody level, RF positivity, and long disease duration as well as obesity, a long-standing history of cigarette smoking, and hypertension all contributed to increasing the risk of developing cardiovascular events and diffuse hypokinesis.
Our patient was almost bedridden and RA disease activity was high at the time of admission. An X-ray of the hands revealed advanced joint deformity. Therefore, we were compelled to introduce TCZ even in the presence of severe HF after he failed to reach the optimal level of disease activity in spite of receiving MTX monotherapy for several months. His RA disease activity has subsequently improved without any marked deteriorations.
Moreover, regular ultrasonography demonstrated that LVEF had remained stable and his serum BNP value had not worsened over the five years. He has not been readmitted to our hospital due to deteriorated HF and has been able to move around in a mobility scooter.
Several studies have reported elevated levels of inflammatory cytokines, such as TNF-α and IL-6, and circulating leukocytes in the plasma of HF patients, as well as in the failing myocardium itself 10−11) . The magnitude of the increase of TNF-α was reported to be directly correlated with the severity of disease, hence the hypothesis that TNF-α might play a role in the pathophysiology of .
A recent study showed that compared to controls, . On the basis of recent genetic evidence in human beings, IL-6R signaling seems to have a causal role in development of coronary heart disease. In 25,458 coronary heart disease cases and 100,740 controls, the IL-6R rs7529229 single nucleotide . Thus, IL-6 blockade could provide a novel therapeutic approach to prevention of coronary heart disease. Our patient was diagnosed with 3-vessel coronary artery disease and severe HFREF at the age of 41 and has been successfully and uneventfully treated by Il-6
blockade TCZ for five years. There is a possibility that TCZ has prevented the further deterioration of HFREF secondary to coronary artery disease for a long period of time. TCZ may be an efficacious treatment option in patients with active RA complicated by severe HF. We need to ascertain the safety and efficacy of TCZ in a larger number of patients with RA accompanied by ischemic heart disease-associated HF.
